Global thought leader in the emerging field of immunotherapy
Dr. Brahmer’s research and clinical practice focus on the development of new therapies, including immunotherapies, for the treatment and prevention of lung cancer and mesothelioma. She was involved in the phase 1 trial of the PD-1 blocking antibody, nivolumab.
Dr. Brahmer is the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Director, Thoracic Oncology Program and Associate Professor of Oncology.
Much of Dr. Brahmer’s work is in the new and exciting field of immunotherapy for lung cancer. This emerging treatment protocol uses a person’s own immune response to treat their disease.
No treatment is approved by the Federal Drug Administration (FDA) without first going through a clinical trial. Without clinical trials, there is no advancement in the science that produces life saving treatments.